Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Q1 2025 Management View CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite ...

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

It offers Rezdiffra, which is a liver-directed thyroid hormone receptor beta agonist for treating MASH. Following its FDA approval in March 2024, Rezdiffra has shown a strong performance in ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO ...

During the quarter, the company generated total revenues of $137.3 million, entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom ...

Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...

CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite typical Q1 industry ...

Bill Sibold, Chief Executive Officer of Madrigal, stated, “Since Rezdiffra’s approval last year, we’ve executed an exceptional launch. We introduced the first FDA-approved treatment for MASH ...